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Abstract
Adipokines are secreted from adipose tissue, influence energy homeostasis and may contribute to 
the association between obesity and hypertension. Among 1,897 participants enrolled in the Multi-
Ethnic Study of Atherosclerosis, we examined associations between blood pressure and leptin, 
tumor necrosis factor – α [TNFα], resistin and total adiponectin. The mean age and body mass 
index was 64.7 years and 28.1 respectively, and 50% were female. After adjustment for risk 
factors, a 1-standard deviation increment higher leptin level was significantly associated with 
higher systolic (5.0 mmHg), diastolic (1.9), mean arterial (2.8) and pulse pressures (3.6), as well 
as a 34% higher odds for being hypertensive (p < 0.01 for all). These associations were not 
materially different when the other adipokines, as well as body mass index, waist circumference or 
waist to hip ratio, were additionally added to the model. Notably, the associations between leptin 
and hypertension were stronger in men, but were not different by race/ethnic group, body mass 
index or smoking status. Adiponectin, resistin and TNFα were not independently associated with 
blood pressure or hypertension. Higher serum leptin, but not adiponectin, resistin or TNFα, is 
associated with higher levels of all measures of blood pressure, as well as a higher odds of 
hypertension, independent of risk factors, anthropometric measures and other selected adipokines.
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INTRODUCTION
Obesity is a significant and pervasive public health problem. As of 2010, over 35% of the 
United States adult population was obese, while just under 17% of US children and 
adolescents were classified as obese.1 Individuals who are overweight or obese are at 
increased risk for developing metabolic disorders, such as the metabolic syndrome, diabetes 
and dyslipidemia, which confer a higher risk for cardiovascular diseases.2, 3 Additionally, 
there is a strong and consistent association between greater adipose tissue and higher levels 
of blood pressure, as well as incident hypertension.4, 5 Indeed, it is estimated that 70% of 
hypertension can be attributed to excess body weight due to adiposity.6
The pathogenesis of obesity-associated hypertension is multifactorial. Increased sympathetic 
nervous system activity, activation of the renin-angiotensin system and volume expansion 
appear to be central determinants of prolonged elevation of systemic blood pressure.7, 8 In 
obese states, sympathetic nervous system activity is increased in the renal nerves, which 
results in increased renal tubular sodium reabsorption and impairs renal-pressure natriuresis 
resulting in increased blood pressure.9, 10 Importantly, the precise mechanisms driving 
increases in renal sympathetic nervous system activity have not been elucidated.
Adipokines are cytokines derived from adipose and related tissues that regulate energy 
utilization primarily by influencing lipid and glucose metabolism in peripheral tissues.11 For 
example, adiponectin modulates insulin sensitivity by decreasing lipid synthesis and glucose 
production in the liver, as well as decreasing triglyceride production and increasing free 
fatty acid oxidation in skeletal muscle. Conversely, leptin regulates energy expenditure by 
inducing satiety, while also increasing hepatic glucose production and its uptake in skeletal 
muscle.12 Given the links between obesity and increased blood pressure, as well as 
adipokines and adipose tissue deposition, we conducted a study to determine whether serum 
adipokine concentrations were associated with blood pressure, as well as diagnoses of both 
hypertension and isolated systolic hypertension. We hypothesized that higher leptin or 
decreasing adiponectin concentrations would be associated with higher blood pressure.
MATERIALS AND METHODS
Participants
The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal cohort study of 
African, Chinese and Hispanic Americans, as well as non-Hispanic Whites. Details about 
the study design have been published.13 In brief, between July 2000 and August 2002, 6,814 
men and women who were 45 to 84 years old and were free of clinically apparent 
cardiovascular disease (CVD) were recruited from 6 United States communities. Individuals 
with a history of physician-diagnosed heart attack, angina, heart failure, stroke or TIA, or 
having undergone an invasive procedure for cardiovascular disease (CABG, angioplasty, 
valve replacement or pacemaker placement) were excluded from participation. Enrolled 
participants returned for follow-up clinic examinations on 3 subsequent visits at 
approximately 18-month intervals. All participants provided written informed consent and 
the institutional review boards (IRB) at the participating Universities approved the study.
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At clinic exams 2 and 3 (approximately 2 – 4 years after the baseline visit), a random 
subsample of 1,970 participants (approximately ½ at each visit) from 5 of the 6 MESA field 
centers enrolled in an ancillary study to determine the presence and extent of calcified 
atherosclerosis in the abdominal aorta using computed tomography.14 The images from 
these scans, and stored venous blood taken contemporaneously, were utilized to determine 
the associations of both abdominal body composition and serum concentrations of 
adipokines with subclinical and clinical CVD. The data obtained on these participants 
comprise the sample for the current study.
Data Collection
At all clinic examinations (including visits 2 and 3 when the abdominal CT scans were 
conducted), standardized questionnaires were used to obtain sociodemographic, race/
ethnicity and health history information. Cigarette smoking was defined as current, former, 
or never. Height and weight were measured with participants wearing light clothing and no 
shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in 
meters squared. Waist and hip circumferences were measured using a standard flexible tape 
measure. Resting blood pressure was measured 3 times in seated participants with a 
Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon). The 
calculation of systolic blood pressure, diastolic blood pressure, pulse pressure and mean 
arterial pressure was based on the average of the second and third readings. Hypertension 
(HTN) was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 
mm Hg, or current use of an antihypertensive medication, while isolated systolic 
hypertension (ISH) was defined as a systolic blood pressure ≥140 mm Hg or current use of 
an antihypertensive medication and a diastolic blood pressure < 90 mmHg.
Laboratory
At all clinic examinations, total and HDL cholesterol, triglycerides, and glucose levels were 
measured from blood samples obtained after a 12-hour fast.15 Fasting blood was also 
assayed for measures of systemic inflammation (CRP, fibrinogen, interleukin-6) and insulin 
concentration. Dyslipidemia was defined as a total-cholesterol/HDL-cholesterol ratio > 5.0 
or if the participant used medication to reduce cholesterol. Diabetes was defined as fasting 
glucose ≥ 126 mg/dL or use of hypoglycemic medication.
Stored fasting blood samples obtained at clinic visits 2 and 3 were analyzed to provide 
serum concentrations of leptin, TNFα, resistin and total adiponectin. These adipokines were 
measured using Bio-Rad Luminex flow cytometry (Millepore, Billerica, MA) at the 
Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT). 
Average analytical coefficients of variation across several control samples for these analytes 
ranged from 6.0–13.0%.
Statistical Analysis
Among the 1,970 potential participants, there were 73 individuals who were missing values 
for the covariates and were excluded from the analysis, resulting in a final analytic sample 
of 1,897 participants. Characteristics of the population were determined with a mean and 
standard deviation for continuous variables, while categorical variables were summarized as 
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a count and percentage of the study population. ANCOVA was used to determine the means 
of adipokines by hypertension status after adjusting for age, gender and race.
The adipokines were log transformed to reduce skewness and outliers. Pearson correlation 
coefficients were generated after adjusting for age, gender and race/ethnicity. So that all 
participants, including those taking blood pressure medications, could be included in the 
analysis, we utilized censored normal regression to assess the association between 
adipokines and continuous measures of blood pressure.16, 17 To determine the association 
between the adipokines and both hypertension and isolated systolic hypertension, we 
utilized unconditional logistic regression and the continuous and categorical (in quartiles) 
forms of the adipokine variables. For all regression analyses, the initial model 1 was 
adjusted for age, gender and race/ethnicity. Models were subsequently adjusted for smoking 
and education (model 2); then cystatin C, diabetes, dyslipidemia and fibrinogen (model 3); 
and finally BMI (model 4), waist circumference (model 5) or the waist to hip ratio (model 
6), separately.
Multiplicative interactions between each adipokine and both race/ethnicity and body mass 
index (separately) were assessed. A two-tailed p-value < 0.05 was considered statistically 
significant and all statistical analyses were conducted using SPSS (Version 19.0; IBM Corp, 
Armonk, New York, USA) and STATA (Version 12; StataCorp, College Station, TX).
RESULTS
Overall, the mean age of the cohort was 64.7 years and 50% were female. Forty percent 
were non-Hispanic White, 26% were Hispanic/Latino, 21% were African American and 
13% were Chinese American. Over half (54%) of the participants were hypertensive and 
44% were taking a blood pressure medication. The mean systolic and diastolic blood 
pressures, as well as pulse and mean arterial pressures, were 124, 70, 54 and 88 mmHg, 
respectively. The mean BMI was 28.1 kg/m2 and 31% were obese. Most (46%) were never 
smokers whereas 43% were former smokers and 11% were current smokers. Forty percent 
were classified as dyslipidemic, 14% were classified as having diabetes mellitus and 6% had 
a positive family history of premature CVD. Mean/median (standard deviation) values for 
adiponectin, leptin, resistin, tumor necrosis factor -α (TNF-α), C-reactive protein (CRP), 
interleukin-6 (IL6) and fibrinogen, were 20.7/17.4 (13.2) μg/ml, 20.9/13.5 (22.3) ng/ml, 
16.3/15.1 (6.8) ng/ml, 5.8/4.6 (9.6) pg/ml, 3.2/1.5 (7.0) mg/l, 2.2/1.9 (7.9) pg/ml and 
434/427 (91.5) mg/dl, respectively.
The characteristics of the study cohort stratified by hypertension status are provided in Table 
1. After adjustment for age, sex and race/ethnicity, those who were hypertensive were 
significantly older, more likely to be African American, to have dyslipidemia, diabetes 
mellitus or a family history of premature CVD. Those with hypertension also had 
significantly higher levels of BMI, cystatin-C, fibrinogen, leptin and resistin, but not CRP, 
IL6 or TNF-α. Adiponectin levels were borderline higher in those without hypertension (p = 
0.08).
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The linear correlations between the blood pressure measures and the natural log transformed 
values of the different adipokines were modest. With adjustment for age, sex and race, the 
strongest significant correlations were between leptin and systolic blood pressure (r = 0.14, 
< 0.01), diastolic blood pressure (r = 0.07, p < 0.01), pulse pressure (r = 0.15, p < 0.01) and 
mean arterial pressure (r = 0.12, p < 0.01). Although not as strong, adiponectin was 
significantly and inversely correlated with all measures of blood pressure: SBP: −0.10, < 
0.01; DBP: −0.06, < 0.01; PP: −0.08, < 0.0 and MAP: −0.09, < 0.01. Resistin was 
significantly associated with and pulse pressure (0.05, 0.03) but none of the other blood 
pressure measures. Tumor necrosis factor -α was not significantly correlated with any of the 
blood pressure measures.
Leptin
After adjustment for age, gender and race/ethnicity, a 1-unit increase in the natural log of 
leptin was associated with a 5.9 mmHg higher SBP (p < 0.01), which decreased to 5.0 
mmHg (p < 0.01) with additional adjustment for education, smoking, cystatin-C, diabetes, 
dyslipidemia and fibrinogen (Table 2). The association was further attenuated, but remained 
statistically significant, with adjustment for BMI (2.3 mmHg, p <0.01), waist circumference 
(2.6 mmHg, p < 0.01) or the waist to hip ratio (3.7 mmHg, p < 0.01). The findings were 
similar for diastolic blood pressure, mean arterial pressure and pulse pressure (see Table 2). 
When leptin was categorized into quartiles (Q1: < 5.6, Q2: 5.6 – 13.5, Q3: 13.5 – 28.3, Q4: 
> 28.3), and even after full adjustment (i.e. model 4), each successive quartile was 
significantly associated with higher SBP, DBP, MAP and PP (Figure 1). Notably, the 
associations appeared particularly strong for the highest quartile and there was a significant 
reduction in the magnitudes of the associations with adjustment for BMI.
After adjustment for age, gender and race/ethnicity, a 1-standard deviation (SD) increase in 
leptin was associated with a 53% higher odds for the presence of hypertension (p < 0.01) 
[Table 3]. This association was not changed with additional adjustment for smoking and 
education, but was attenuated to 34% (p < 0.01) when cystatin-C, diabetes, dyslipidemia and 
fibrinogen were added to the model and then became non-significant when BMI was also 
included (1.09, p = 0.22). The results were similar when BMI was replaced by waist 
circumference or the waist to hip ratio (separately). Notably, when leptin was categorized 
into quartiles, there was a graded relationship between each successively higher quartile and 
the odds for the presence of hypertension (Figure 2). Specifically, with adjustment for age, 
gender and race/ethnicity and compared to the lowest quartile (Q1), the second (Q2), third 
(Q3) and fourth (Q4) quartiles were associated with 1.93, 2.25 and 3.88 higher odds for 
hypertension (p < 0.01 for all). With adjustment for all of the variables listed above, 
including BMI, these odds ratios were moderately attenuated (1.60, 1.60 and 2.04, 
respectively) but remained statistically significant (p < 0.01 for all). The findings were 
similar when BMI was replaced by waist circumference or the waist to hip ratio. All of the 
findings described above were similar when ISH was the outcome variable.
As the distribution of leptin has been shown to differ significantly by gender across different 
ethnic groups18, we conducted analyses stratified by this variable. After full adjustment and 
among men, a 1-unit increment in the natural log of leptin was associated with 1.6, 1.1, 1.2 
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and 0.8 mmHg higher SBP, DBP, MAP and PP levels respectively, while, among women, 
this same increment in leptin was associated with 2.3, 1.3, 1.6 and 1.4 mmHg higher SBP, 
DBP, MAP and PP levels. The odds for hypertension were somewhat higher in men (1.26 
vs. 1.10). We then examined the same associations but using gender specific quartiles of 
leptin (Table 4). Among women, there was a stepwise increase in the strength of the 
association between leptin and all of the measures of blood pressure, as well as the odds for 
hypertension. For example, women in the 2nd, 3rd and 4th quartiles of leptin had systolic 
blood pressure values that were 0.0, 2.4 and 5.2 mmHg higher respectively, compared to 
those in the 1st quartile. Conversely, among men, the strongest association for the different 
measures of blood pressure was for those in the third quartile of leptin, while those in the 
highest quartile had the highest odds for being classified as hypertension. Despite the 
differences in the shape of the associations for men and women, the magnitudes where 
somewhat similar between these two groups, with the exception of the odds for 
hypertension, which were higher among men.
There were no significant interactions between leptin and race/ethnicity, BMI or smoking 
status.
Total Adiponectin
As shown in Table 2, after adjustment for age, gender and race/ethnicity, higher total 
adiponectin was associated with significantly lower values of SBP, DBP, MAP and PP (p < 
0.01 for all). These associations remained significant after additional adjustment for 
education, smoking, diabetes, dyslipidemia, cystatin-C and fibrinogen, but not BMI. 
Similarly, compared to the lowest quartile (Q1: < 11.8, Q2: 11.8 – 17.4, Q3: 17.4 – 26.3, 
Q4: > 26.3), the highest quartile of adiponectin was significantly associated with 
significantly lower levels of all of the blood pressure measures, but the associations became 
not statistically significant when BMI was added to the models (data not shown).
A 1-SD increment in adiponectin was associated with significantly lower odds for 
hypertension after adjustment for age, gender, race/ethnicity, smoking and education (OR = 
0.89, p = 0.03). However, this association was no longer significant when diabetes, 
dyslipidemia, cystatin-C and fibrinogen were added to the model (0.92, p = 0.15). Also, and 
unlike the case with leptin, different quartiles of adiponectin were not significantly 
associated with hypertension after adjustment. The results were consistent when ISH was the 
outcome variable.
Resistin and Tumor Necrosis Factor -α
There were no consistent significant associations between either resistin or TNF -α (as 
continuous or quartile variables) and the different measures of blood pressure, HTN or ISH.
DISCUSSION
In this study of a large, multi-ethnic population-based cohort from multiple sites across the 
United States, higher leptin concentrations were associated with higher levels of systolic, 
diastolic, mean and pulse pressures, as well as diagnoses of both hypertension and isolated 
systolic hypertension, independent of relevant covariates including body mass index or other 
Allison et al. Page 6
J Hum Hypertens. Author manuscript; available in PMC 2014 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
measures of body morphology. Indeed, after multivariable adjustment, those with leptin 
concentrations in the highest quartile had over a 2-fold higher odds of hypertension. On the 
other hand, adiponectin was associated with lower levels of blood pressure and odds for 
hypertension or ISH, but these associations were not independent of other risk factors and, 
in particular, adiposity. Finally, neither resistin nor tumor necrosis factor -α were 
consistently associated with the different measures of blood pressure or hypertension. Taken 
together, these results suggest that leptin may be influencing blood pressure levels by a 
mechanism distinct from adiposity and other relevant risk factors while the same cannot be 
said for adiponectin and both resistin and tumor necrosis factor – α do not appear to 
significantly influence blood pressure.
Of note, the associations between leptin and higher blood pressure, as well as being 
classified as hypertensive, were independent of risk factors, total body adiposity and other 
selected measures of adiposity-associated inflammation. Additionally, the results of our 
study suggest that gender may modify the association between leptin and blood pressure. 
While the magnitudes of the associations were similar for the different continuous measures 
of blood pressure (i.e. SBP, DBP, MAP, PP), compared to women, higher leptin levels in 
men were associated with significantly higher odds for being classified with hypertension. In 
contrast, the associations were not significantly different by ethnicity, level of adiposity (by 
BMI categories) or smoking status.
A potential mechanism by which obesity may increase blood pressure is via increased 
sympathetic activity due to hyperleptinemia.19 Animals with diet-induced obesity, as well as 
most obese humans, are hyperleptinemic.20 Leptin is a cytokine secreted by adipose tissue 
that acts on the hypothalamus to decrease food intake via appetite suppression, while also 
increasing energy expenditure through sympathetic nervous system activity in the kidneys, 
adrenals and brown adipose tissue (BAT).19, 21, 22 Notably, there is a differential effect of 
leptin on BAT and the renal sympathetic nervous system activity. Specifically, increased 
blood pressure attenuates the effect of leptin on renal sympathetic fibers but does not affect 
its effect on fibers innervating BAT. Conversely, hypothermia augments the effect of leptin 
on BAT but not on renal sympathetic nerves.23, 24 These data suggest that the effect of leptin 
on renal sympathetic fibers is involved in the regulation of hemodynamics whereas its effect 
on BAT sympathetic nervous system activity is associated with temperature homeostasis.
Additionally, several studies have reported that the administration of leptin by various 
methods increases natriuresis without affecting renal blood flow, glomerular filtration rate or 
potassium excretion, suggesting that the natriuretic effect of leptin results from inhibiting 
tubular Na+ reabsorption.25–27 Indeed, both Shek28 and Kuo29 have demonstrated that leptin 
infusions resulting in concentrations similar to those observed in obese individuals increases 
mean arterial pressure while renal Na+ excretion is not changed. The importance of leptin as 
a regulator of sodium and volume is further supported by recent investigations showing that 
leptin expression in adipose tissue is directly proportional to dietary sodium, a response that 
would be expected for mechanisms regulating sodium balance.30
Due to the consistent and robust associations between leptin and blood pressure/
hypertension, the results of our study provide strong support for the hypothesis that leptin is 
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relevant to the kidney’s regulation of blood pressure. This finding is corroborated by results 
from other studies. For example, the Copenhagen City Heart Study reported that, when 
included in the same multivariable model, leptin, but not adiponectin, was significantly 
associated with incident hypertension.31 Concomitantly, that this association appears to be 
independent of adiposity is consistent with prior results. For example, a study of 
normotensive males has reported that there is a significant correlation between plasma leptin 
and blood pressure independent of body mass or abdominal obesity32 and even those of 
normal body weight but essential hypertension have significantly higher plasma leptin.33 
Additionally, leptin-deficient humans show decreased sympathetic tone and normal blood 
pressure despite severe obesity.34 As such, the existing literature on the association between 
leptin and blood pressure supports and independent effect of this adipokine.
From a clinical perspective, higher levels of leptin have been associated with CVD risk 
factors that influence vascular function relevant to blood pressure regulation. These include 
diabetes mellitus and arterial compliance.35, 36 Given the association between higher leptin 
and higher blood pressure, interventions that reduce leptin concentrations may have salutary 
effects on blood pressure and CVD risk. In this regard, previous trials have shown that 
higher levels of physical activity and/or a diet low in saturated fat are associated with 
significant reductions in leptin concentrations, independent of changes in fat mass or body 
mass index.37 Similarly, we have shown that higher levels of sedentary activity are 
associated with higher leptin concentrations independent of body mass index and physical 
activity levels.38 Notably, there are no approved therapeutic interventions to lower leptin. As 
such, recommendations for lifestyle modifications that reduce sedentary behavior, increase 
physical activity or include a diet with less saturated fat may reduce leptin concentrations 
and therefore the risk of developing hypertension.
Strengths of this study include a relatively large, well-characterized, multi-ethnic cohort 
from across the United States and valid and reproducible measures of four different 
adipokines. Limitations include few subjects at the highest levels of obesity and a cross-
sectional study design, which limits inferences on causality. Indeed, it may be possible that 
there is residual confounding due to an unmeasured cytokine. In this regard, longitudinal 
studies of those who are not hypertensive at baseline would minimize the potential for errors 
in interpretation due to reverse causality.
In conclusion, higher concentrations of leptin are associated with higher systolic, diastolic, 
pulse and mean arterial pressures, as well as being classified as hypertensive or with isolated 
systolic hypertension, independent of relevant risk factors, measures of adiposity and 
selected measures of adiposity-associated inflammation, and these associations may to be 
stronger among women. These findings provide evidence that leptin may be influencing 
blood pressure independently and by an as yet determined mechanism.
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What is known about this topic
1. Obesity is associated with high blood pressure.
2. Adipokines are related to higher levels of adiposity.
3. Leptin has been associated with hypertension.
What this study adds
1. Leptin is significantly associated with multiple measures of blood pressure 
(SBP, DBP, pulse pressure and mean arterial pressure) and both hypertension 
and isolated systolic hypertension.
2. The associations between leptin and blood pressure are independent of relevant 
risk factors, several measures of obesity and selected measures of adiposity-
associated inflammation.
3. The association between leptin and blood pressure appear to be different by 
gender but not race/ethnicity, level of obesity or smoking status.
4. The association between adiponectin and blood pressure is not independent of 
adiposity.
5. Resistin and tumor necrosis factor -α are not significantly associated with blood 
pressure or hypertension.
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FIGURE 1. ASSOCIATIONS BETWEEN QUARTILES OF LEPTIN AND DIFFERENT 
MEASURES OF BLOOD PRESSURE
Referent Category = Quartile 1; Q2 = 2nd Quartile, Q3 = 3rd Quartile, Q4 = 4th Quartile
SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure, MAP = Mean Arterial 
Pressure, PP = Pulse Pressure
Model 1: age, gender, race
Model 2: model 1 + smoking, education
Model 3: model 2 + cystatin C, diabetes, dyslipidemia, fibrinogen
Model 4: model 3 + body mass index
All values significant at p < 0.05
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FIGURE 2. ODDS OF HYPERTENSION BY QUARTILE OF LEPTIN
Reference Group = First quartile of leptin
Model 1: age, gender, race
Model 2: model 1 + smoking, education
Model 3: model 2 + cystatin C, diabetes, dyslipidemia, fibrinogen
Model 4: model 3 + body mass index
All values significant with p < 0.01
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TABLE 1
COHORT CHARACTERISTICS
Characteristic* HTN (N = 1033) No HTN (N = 864) p-value
Age (years) 67.4 61.5 < 0.01
Gender (Male) 51.0% 49.0% 0.40
Ethnicity
 Caucasian 40.1% 40.1% 0.97
 Asian 10.5% 15.9% <0.01
 African American 26.0% 15.0% <0.01
 Hispanic 23.4% 29.0% <0.01
Education (more than HS) 63.3% 65.6% 0.29
Ever Smoker 55.0% 52.5% 0.90
Body Mass Index (kg/m2) 29.2 26.9 < 0.01
Systolic Blood Pressure (mmHg) 131.8 114.7 <0.01
Diastolic Blood pressure (mmHg) 72.4 67.3 <0.01
Mean Arterial Pressure (mmHg) 92.2 83.1 <0.01
Pulse Pressure (mmHg) 59.5 47.4 <0.01
Diabetes Mellitus 20.7% 7.0% < 0.01
Dyslipidemia 45.2% 34.5% < 0.01
Family History of CVD 10.5% 0.8% 0.11
C-reactive Protein (mg/l) 3.34 3.05 0.39
Interleukin-6 (pg/ml) 2.22 2.18 0.92
Fibrinogen (mg/dl) 438 429 0.02
Adiponectin (μg/ml) 20.2 21.3 0.076
Leptin (ng/ml) 24.1 17.0 <0.01
Resistin (ng/ml) 16.8 15.9 0.03
Tumor Necrosis Factor - α (pg/ml) 5.61 4.89 0.42
*All adjusted for age, gender, and race (except when it is the variable of interest)
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